July 22nd, 2021
Deal Struck to Distribute Ruconest in Middle East, North Africa
July 19th, 2021
Early Phase 1 Data Support PHA121 as Oral HAE Prophylactic
July 15th, 2021
Understanding and Managing Hereditary Angioedema Triggers
July 12th, 2021
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE
July 12th, 2021
Interim Data Support Long-term Safety of Orladeyo for HAE Attacks
July 10th, 2021
New data from the Phase 3 HELP Study™ Open Label Expansion to evaluate the safety and efficacy of TAKHZYRO® (lanadelumab) in patients with hereditary angioedema will be announced at the European Society of Allergy and Clinical Immunology (EAACI) Hybrid Co
July 10th, 2021
America Recognizes Chronic Disease Day 2021 with Good Days
July 9th, 2021
Boston Bridges Light Up Orange & White for Chronic Disease Day & Good Days
July 9th, 2021
Children's Book Series Helps Kids Cope with Hereditary Angioedema
July 8th, 2021
Companies Join to Advance OTL-105, Potential Gene Therapy for HAE
July 1st, 2021
Orchard Therapeutics Inks Strategic Deal to Develop HSC Gene Therapy for Hereditary Angioedema
June 30th, 2021
Psychosocial burden of type 1 and 2 hereditary angioedema: A single-center Canadian cohort study
June 28th, 2021
In Major CRISPR Milestone, INTELLIA Successfully Edits Genes Inside Body
June 14th, 2021
Oral PHA121 May Lead to Faster, More Durable Effects Than Firazyr
June 11th, 2021
New Children’s Book Series Helps Kids Cope with Ultra-Rare Chronic Condition
June 5th, 2021
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop
May 25th, 2021
BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo
May 24th, 2021
Pharma, Patient Associations Join Efforts for HAE Awareness Day
May 18th, 2021
Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
May 17th, 2021
Pharming celebrates the 10th annual "hae day :-)
May 10th, 2021
Japanese Researchers Identify New Gene Mutation Linked to HAE
May 9th, 2021
The Genetics of Hereditary Angioedema: A Review
May 3rd, 2021
Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks
April 29th, 2021
Supporters ‘Take Next Step’ Toward HAE Awareness Day on May 16
April 23rd, 2021
Prophylactic treatment in hereditary angioedema is associated with reduced anxiety in patients in Leipzig, Germany
April 19th, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
April 13th, 2021
Impact of lanadelumab on health related quality of life in patients with hereditary angioedema in the HELP study
April 12th, 2021
Life Quality Gains Evident With Newer Preventive HAE Therapies, Survey Finds
March 29th, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
March 23rd, 2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women
March 22nd, 2021
Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials
March 18th, 2021
Orladeyo Now Available in France Via Early Access Program
March 17th, 2021
Patient-researcher collaboration proves to be a win-win, Japanese study shows
March 12th, 2021
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
March 11th, 2021
Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema
March 11th, 2021
Screening for Plasminogen Mutations in Hereditary Angioedema Patients Genes Article MDPI
March 11th, 2021
Biocryst’s berotralstat granted early access for HAE in France
March 11th, 2021
Orphan product designation requests climb in the US, remain steady in the EU
March 11th, 2021
First Patient Dosed in Phase 2 Trial Testing PHVS416 for HAE Attacks
March 8th, 2021
Interim Trial Data of Gene-editing Therapy NTLA-2001 Expected This Year
March 5th, 2021
Long-term Haegarda Found to Improve Quality of Life in HAE Patients
March 3rd, 2021
BioCryst Pharma (BCRX) Submits MAA for UK Approval of ORLADEYO, an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
March 1st, 2021
Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks
February 26th, 2021
Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers
February 25th, 2021
Oral Hereditary Angioedema Treatment Provides Effective Bradykinin-Inhibiting Concentrations
February 23rd, 2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women
February 19th, 2021
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
February 18th, 2021
HAE Patients in US Favored Oral Prophylactic in 2018 Survey
February 15th, 2021
Stress Can Affect Patients’ Mental Health, How They Manage Their Care
February 8th, 2021
Menopause Found to Not Worsen HAE in Most Women
February 8th, 2021
Optimal Management of HAE: Shared Decision Making
January 9th, 2021
Psychological processes in the experience of hereditary angioedema in adult patients: an observational study
December 3rd, 2020
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
December 1st, 2020
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults
November 20th, 2020
New Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1 INH Deficiency When Choosing an HAE Therapy
October 15th, 2020
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise
September 29th, 2020
U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
May 15th, 2020
BioCryst Celebrates HAE Patients with HAE Global Walk
May 4th, 2020
CSL Behring is Committed to Supporting Patients
May 1st, 2020
Pharming to Support Patients Continuity in Care
April 22nd, 2020
Takeda Expands Patient Assistance in the U.S. During COVID-19 Crisis
April 21st, 2020
Pharming reports encouraging results from use of RUCONEST® in COVID-19 patients
April 6th, 2020
Mensaje de la Directora de Salud de la HAEA, Lois Perry
April 6th, 2020
A Message from the Director of HAE Health Lois Perry
April 6th, 2020
GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY
March 19th, 2020
An Important Message Regarding HAEA Upcoming Events
March 18th, 2020
How Our Pharmaceutical Companies Are Managing the Coronavirus Situation.
March 6th, 2020
A Message from HAEA Nurse Case Manager Troyce Venturella
January 13th, 2020
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise
November 27th, 2018
JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema
August 23rd, 2018
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
June 21st, 2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients
May 16th, 2018
KalVista Pharmaceuticals Recognizes HAE Day
April 9th, 2018
HAEA comments on ICER HAE therapy assessment
February 25th, 2018
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
February 15th, 2018
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
January 24th, 2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
January 22nd, 2018
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
January 8th, 2018
A Big Pharma-funded charity that helps patients pay for drugs just sued the government
January 5th, 2018
KalVista Pharmaceuticals Commences Two Clinical Trials
September 29th, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema
September 14th, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results
September 11th, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
September 11th, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE
September 5th, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
July 26th, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet
July 23rd, 2017
FDA Approves HAEGARDA® King Of Prussia, PA
June 22nd, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease
May 24th, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
May 24th, 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
April 13th, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
March 23rd, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients
October 1st, 2016
Elucidating the Mechanism of Gain of Toxic Function From Mutant C1 Inhibitor Proteins in Hereditary Angioedema
Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers
